| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 06/18/2013 | CA2459348C Antibodies to non-functional p2x7receptor, diagnosis and treatment of cancers and other conditions |
| 06/18/2013 | CA2446087C Recombinant tumor specific antibody and use thereof |
| 06/18/2013 | CA2422002C Vaccine |
| 06/18/2013 | CA2418144C Urocortin proteins and uses thereof |
| 06/18/2013 | CA2415187C Dna vaccines encoding hiv accessory proteins |
| 06/13/2013 | WO2013086533A1 Neutralizing antibodies to hiv-1 and their use |
| 06/13/2013 | WO2013086515A1 Compositions and methods for the prevention or treatment of diabetic complications |
| 06/13/2013 | WO2013086506A1 Idh1-mutated human glioblastoma cell lines and xenografts |
| 06/13/2013 | WO2013086500A1 Artificial antigen presenting cells having a defined and dynamic shape |
| 06/13/2013 | WO2013086443A1 Agonistic human lcat antigen binding proteins and their use in therapy |
| 06/13/2013 | WO2013086418A1 Tumor-specifc gm-csf cytokine response as predictor of cancer vaccine effectiveness |
| 06/13/2013 | WO2013086260A2 Combination therapy for treatment of cancer |
| 06/13/2013 | WO2013086052A2 Antibodies useful in passive influenza immunization |
| 06/13/2013 | WO2013085973A1 Treatment for angiogenic disorders |
| 06/13/2013 | WO2013085972A1 Pdgf receptor beta binding polypeptides |
| 06/13/2013 | WO2013085893A1 Therapeutic use of anti-cd22 antibodies for inducing trogocytosis |
| 06/13/2013 | WO2013085889A1 Identification and cloning of transmitted hepatitic c virus (hcv) genomes by single genome amplification |
| 06/13/2013 | WO2013085550A2 V1v2 immunogens |
| 06/13/2013 | WO2013085021A1 Composition for enhancing antibody production |
| 06/13/2013 | WO2013084250A1 Combination of cyclophosphamide and dendritic cells for use in the treatment of uterine cervix carcinoma |
| 06/13/2013 | WO2013084236A1 Diagnostic and therapeutic methods and their application in amyotrophic lateral sclerosis (als) |
| 06/13/2013 | WO2013084071A2 Clostridium difficile toxin-based vaccine |
| 06/13/2013 | WO2013084070A2 Salmonella vaccine proteins |
| 06/13/2013 | WO2013084001A1 Exosomes with transferrin peptides |
| 06/13/2013 | WO2013084000A2 Exosomes for delivery of biotherapeutics |
| 06/13/2013 | WO2013083809A1 Prevention of adverse effects caused by epcamxcd3 bispecific antibodies |
| 06/13/2013 | WO2013083726A1 Aluminium compounds for use in therapeutics and vaccines |
| 06/13/2013 | WO2013083659A1 Combination treatment comprising ho - 1 inhibitor and immunotherapeutic agent |
| 06/13/2013 | WO2013083497A1 Antibody formulation |
| 06/13/2013 | WO2013083287A1 Hpv derived polynucleic acids for therapy |
| 06/13/2013 | WO2013083254A1 Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c |
| 06/13/2013 | WO2013083095A1 Novel antibiotic preparation method and platform system based on same |
| 06/13/2013 | WO2013083036A1 Porcine circovirus type-2 subunit vaccine |
| 06/13/2013 | WO2013058833A8 Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| 06/13/2013 | WO2013056851A3 Stable multiple antigen-binding antibody |
| 06/13/2013 | WO2013055058A9 Antibody-binding peptide-ferritin fusion protein and uses thereof |
| 06/13/2013 | WO2013045707A3 Biological materials related to c-met |
| 06/13/2013 | WO2013036574A4 Modified forms of pseudomonas exotoxin a |
| 06/13/2013 | WO2013016648A3 Stabilized formulations containing anti-pcsk9 antibodies |
| 06/13/2013 | WO2012162565A3 Method for inducing an immune response for treatment of cancer and autoimmune diseases or conditions |
| 06/13/2013 | US20130150296 Albumin fusion proteins |
| 06/13/2013 | US20130149719 Proteins Expressed by Mycobacterium Tuberculosis and not by BCG and Their Use as Diagnostic Reagents |
| 06/13/2013 | US20130149670 Methods, articles and kits for allergic desensitization, via the oral mucosa |
| 06/13/2013 | US20130149384 Thermal inactivation of rotavirus |
| 06/13/2013 | US20130149376 Vaccine composition based on sticholysin encapsulated into liposomes |
| 06/13/2013 | US20130149340 Yeast-Based Vaccines As Immunotherapy |
| 06/13/2013 | US20130149338 Compositions and methods for rapid immunization against dengue virus |
| 06/13/2013 | US20130149337 Method of controlling administration of cancer antigen |
| 06/13/2013 | US20130149334 Chimeric infectious dna clones, chimeric porcine circoviruses and uses thereof |
| 06/13/2013 | US20130149332 Methods for Enhanced Somatostatin Immunogenicity in the Treatment of Obesity |
| 06/13/2013 | US20130149330 Pharmaceutical compositions and methods of blocking bacillus anthracis |
| 06/13/2013 | US20130149329 Broadly protective shigella vaccine based on type iii secretion apparatus proteins |
| 06/13/2013 | US20130149328 Plant-derived cholera and malaria vaccine |
| 06/13/2013 | US20130149327 Yersinia pestis antigens, vaccine compositions, and related methods |
| 06/13/2013 | US20130149326 Adjuvanting meningococcal factor h binding protein |
| 06/13/2013 | US20130149325 Porphyromonas gingivalis polypeptides and nucleotides |
| 06/13/2013 | US20130149324 Therapeutic tb vaccine |
| 06/13/2013 | US20130149323 Mutated lentiviral env proteins and their use as drugs |
| 06/13/2013 | US20130149320 Asf1b as a Prognosis Marker and Therapeutic Target in Human Cancer |
| 06/13/2013 | US20130149319 Anticancer composition |
| 06/13/2013 | US20130149317 Malaria vaccine |
| 06/13/2013 | US20130149314 p19Arf, HMGA2 and MDM2 For Use in the Diagnosis and Treatment of Aberrant Cell Growth |
| 06/13/2013 | US20130149312 Compositions and methods for treating copd exacerbation |
| 06/13/2013 | US20130149311 Gfi1b modulation and uses thereof |
| 06/13/2013 | US20130149310 Compositions for the treatment of rheumatoid arthritis and methods of using same |
| 06/13/2013 | US20130149307 Humanized anti-egfl7 antibodies and methods using same |
| 06/13/2013 | US20130149306 Antagonists of Sema3E/PlexinD1 interaction as anti-cancer agents |
| 06/13/2013 | US20130149305 Soluble cd80 as a therapeutic to reverse immune supression in cancer patients |
| 06/13/2013 | US20130149304 Use of modulators of compounds of tgf-beta superfamily to regulate hepcidin-mediated iron metabolism |
| 06/13/2013 | US20130149303 IMMUNOTHERAPEUTIC METHOD INVOLVING CD123 (IL-3Ra) ANTIBODIES AND IMMUNOSTIMULATING COMPLEX |
| 06/13/2013 | US20130149302 Therapeutic agents for pancreatic cancer |
| 06/13/2013 | US20130149299 Dosages for treatment with anti-egfr antibodies |
| 06/13/2013 | US20130149298 Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin |
| 06/13/2013 | US20130149280 Preparative regimen for engraftment, growth and differentiation of non-hematopoeitic cells in vivo after transplantation |
| 06/13/2013 | US20130149238 Anti-VEGF Antibody Compositions and Methods |
| 06/13/2013 | US20130149237 Delivery system for diagnostic and therapeutic agents |
| 06/13/2013 | US20130149236 Antibodies Reactive with B7-H3, Immunologically Active Fragments Thereof and Uses Thereof |
| 06/13/2013 | CA2858716A1 Neutralizing antibodies to hiv-1 and their use |
| 06/13/2013 | CA2858572A1 Agonistic human lcat antigen binding proteins and their use in therapy |
| 06/13/2013 | CA2858519A1 Clostridium difficile toxin-based vaccine |
| 06/13/2013 | CA2858347A1 V1v2 immunogens |
| 06/13/2013 | CA2858115A1 Artificial antigen presenting cells having a defined and dynamic shape |
| 06/13/2013 | CA2858012A1 Antibodies for epidermal growth factor receptor 3 (her3) |
| 06/13/2013 | CA2857976A1 Novel antibiotic preparation method and platform system based on same |
| 06/13/2013 | CA2857721A1 Pdgf receptor beta binding polypeptides |
| 06/13/2013 | CA2857601A1 Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3 |
| 06/13/2013 | CA2853138A1 Therapeutic use of anti-cd22 antibodies for inducing trogocytosis |
| 06/12/2013 | EP2601970A1 Norovirus vaccine formulations |
| 06/12/2013 | EP2601969A2 Norovirus vaccine formulations |
| 06/12/2013 | EP2601968A1 HPV derived polynucleic acids for therapy |
| 06/12/2013 | EP2601967A1 Drug and method for the prophylaxis of hiv infection and for the prophylaxis and treatment of diseases caused by or associated with hiv, including aids |
| 06/12/2013 | EP2601966A1 Treatment of neurological or neurodegenerative disorders |
| 06/12/2013 | EP2601961A1 Use of Recombinant LAG-3 or the Derivatives Thereof for Eliciting Monocyte Immune Response |
| 06/12/2013 | EP2601934A1 Vesicular phospholipid gels comprising proteinaceous substances |
| 06/12/2013 | EP2601933A1 Hydrophilic filtration during manufacture of vaccine adjuvants |
| 06/12/2013 | EP2601529A2 Biomarkers for prostate cancer and methods for their detection |
| 06/12/2013 | EP2601222A1 Glycolipid for treatment of ischemia reperfusion injury |
| 06/12/2013 | EP2601219A2 Combination pharmaceutical composition and methods of treating and preventing the infectious diseases |
| 06/12/2013 | EP2601217A2 Antibodies directed against il-17 |
| 06/12/2013 | EP2601203A1 Fatty acid esters of carotenoid glucosides as colouring agents for foodstuffs |